Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the captcha-bank domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the email-users domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home1/c306474/public_html/wp-includes/functions.php on line 6131 malaria Archives - Page 3 of 8 - TalkAfrique Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home1/c306474/public_html/wp-includes/functions.php on line 6131
Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home1/c306474/public_html/wp-includes/functions.php on line 6131
This image, put together by a UC Riverside researcher, shows the head and olfactory organs of a female mosquito (in foreground) and a fruitfly (background). The red lines are sample electrical recordings from a CO2-sensitive neuron. The red and black molecules show the chemical structures of compounds the research team tested. (Stephanie Turner)
As summer begins, thoughts often turn to hot dogs, hamburgers, watermelon … and mosquitoes.
For most barbecuers, the bugs are little more than a pesky annoyance. But for millions around the world every year, mosquitoes carrying diseases such as malaria, dengue fever and West Nile virus prove deadly. Mosquito nets and repellants help fight bites, but public health officials still seek cheaper and more effective ways to fight mosquito-borne disease.
Enter researchers at UC Riverside, who reported Wednesday in the journal Nature on three classes of odor molecules that could potentially keep mosquitoes away from people. The chemicals work by blocking the mosquitoes’ ability to detect carbon dioxide — the key cue that leads the insects to their human victims. Mosquitoes zero in on exhaled breath to find you and make you their lunch.
The types of odor molecules work in three ways. The first set inhibits mosquitoes’ and flies’ carbon-dioxide receptors. The second set mimics carbon dioxide. The third set overstimulates carbon-dioxide-sensing neurons, making them unable to detect CO2 for several minutes.
Though the compounds haven’t yet been approved for use in humans, UC Riverside researchers think they might be used to create traps that could replace the bulky and expensive CO2-spewing models in use today.
“Odor molecules that mimic carbon dioxide activity … can lead to the development of small and inexpensive lures to trap mosquitoes — a great benefit, especially to developing countries,” said Anandasankar Ray, an assistant professor of entomology at UC Riverside, in a press release.
The research, which included wind-tunnel experiments and other tests, tested the compounds on three disease-carrying mosquitoes: Anopheles gambiae (which transits malaria), Aedes aegypti (dengue and yellow fever) and Culex quinquefasciatus (West Nile virus and filariasis, also known as elephantiasis). The work was funded by the Bill and Melinda Gates foundation.
UC Riverside has patents on the discovery, which it has licensed to a new startup, Olfactor Labs. The company plans to have product prototypes in 2012.
Los Angeles Times reporter Amina Khan wrote in April about efforts to engineergenes to fight malaria and in February about a mosquito subspecies that was making work harder for health workers.
By Eryn Brown, Los Angeles Times / for the Booster Shots blog
Mr Bill Gates: co-chair of the Bill & Melinda Gates Foundation
Mr. President, Prime Minister Sheikh Hasina, Director-General Dr. Margaret Chan, Excellencies, ladies and gentlemen.
The World Health Organization and this assembly have set the standard for global cooperation in pursuit of better health. For decades, you have established ambitious goals, such as eradicating smallpox. And you have rallied the world to accomplish those goals. It is an honor to join you today.
I had the privilege of addressing this assembly in 2005, when my wife Melinda and I were new to global health. At that time, we were so optimistic about the future. The world was finally starting to use its greatest resource, innovation, to solve this difficult problem – the fact that billions of people don’t have the chance to lead a healthy, productive life.
In the past six years, my optimism has continued to grow.
An recent important new book Getting Better by the economist Charles Kenny shows that life is getting better, rapidly, for people in poor countries. To build his argument, he examines a series of key quality-of-life indicators, including child survival, school enrollment, and levels of violence.
I hope this book gets the acclaim it deserves. It proves that the great work this assembly has been leading is having an enormous impact. We need the people who make funding decisions and set policy to understand the progress being achieved every day. I believe we have the opportunity to make even more progress, faster, for more people.
This opportunity is the reason I devoted my time to the Gates Foundation. Health and development is the most rewarding work I can think of, and Melinda and I will devote the rest of our lives to it.
When I was a teenager, I was captivated by computers because I believed they would change the world. I couldn’t predict exactly what the future would look like, but I was amazed by a sense to improve and empower.
Over the years, as I watched so much change taking root, I also saw glimpses of what was not changing. In 1994, I traveled to sub-Saharan Africa. It was impossible to ignore the devastating impact of disease and poverty on people’s lives.
Then, in 1998, Melinda and I read an article about rotavirus. We learned that it was the leading cause of diarrhea in young children – and that it caused 500 000 deaths annually. Our first child had just been born, and there was a good chance she’d suffered from rotavirus. But in the United States, children don’t die from diarrhea, so this was not a worry for us.
We’d never been forced to reckon with rotavirus, in fact, we’d never even heard of it because there was no chance our daughter would be killed by it.
This was a sobering realization for me. I had built my life around the idea that innovation is for everyone. When I began to understand how billions of people are deprived of its benefits, it made me angry. That’s when I decided to use my personal wealth would be used to help confront that inequity.
Thirty years ago, when I founded Microsoft my colleagues and I envisioned a computer for everyone. Now, I join you in seeking good health care for every human being.
At the Gates Foundation, our goal is to spur innovation on health problems.
Our priorities are your priorities: to make motherhood safer; to ensure that newborns survive their first 30 days; to provide children with a nutritious diet.
We see what you see everyday – that diseases like HIV, tuberculosis, and malaria can destroy communities. Along with great partners like the Global Fund, we want to help you diagnose, treat, and above all, prevent disease.
As we think about how to deploy our resources most effectively, one intervention stands out: vaccines.
Today, I would like to talk about how you can provide the leadership to make this the Decade of Vaccines.
Vaccines are an extremely elegant technology. They can be inexpensive, they are easy to deliver, and they are proven to protect children lifelong from disease. At Microsoft, we dreamed about technologies that were so powerful and yet so simple. Today, I like to imagine what the future will look like when world leaders start to take full advantage of vaccines.
In this Decade, we can achieve a lot.
Early in this decade, we will eradicate polio.
By the end of the decade, five or six new vaccines will be available to all children of the world.
And, crucially, every country in the world will have built a delivery system made to get vaccines to every last child.
To put an end to polio and reach all children with new vaccines, we must create strong immunization programmes.
In January of last year, I called for the world to accelerate progress on vaccines. That was a moment, and now there is momentum. I’m excited that global health leaders are now collaborating to put a specific global vaccine action plan in place.
The success of that plan will be a blueprint for the success of the Decade of Vaccines. It will depend on us to do our best work.
Vaccines and immunization
The greatest asset of every country is the energy and talent of its people. Disease saps that energy and squanders that talent. Repeated intestinal infections stunt children’s growth and reduce their cognitive development. Meningitis can cause permanent neurologic disability. Malaria prevents people from being productive; over a lifetime, high rates of malaria are cause substantially reduced earnings.
That’s why vaccines are one of the best investments we can make in the future: healthy people drive thriving economies. As we free billions of people from the relentless burden of sickness and death will unleash more human potential than ever before.
Let me give you an example of the difference vaccines can make.
This year, 20 million children will have severe pneumonia. More than a million will die. But even when the disease doesn’t take a child’s life, it can affect the child’s and family’s future.
For the survivors, the sickness reduces their chances of growing up healthy and strong. Their parents will go into debt. But we now have vaccines against two of the leading causes of pneumonia which make it possible for countries to reduce the burden and tap into people’s energy and nurture their talent.
Product development
The pneumonia vaccines are a symbol of one of the most exciting trends in global health, the drive towards equity in delivering innovations.
In the past, innovations developed vaccines for rich countries, and it took more than a decade before they were introduced in poor countries. But that is changing.
The newest pneumonia vaccines were available in developing countries only a few years after they were approved for use in developed countries. The same is true of a new rotavirus vaccine. But approved and available don’t mean delivered. Now it is up to the GAVI Alliance and many of you in this room to ensure that these vaccines reach the children who need them.
Last December, Burkina Faso, Mali, and Niger made history when they introduced a brand new vaccine for Meningitis A, the first vaccine developed specifically for use in Africa.
The story began in 1996, when the deadliest meningitis epidemic in memory tore through 25 countries in Africa, infecting more than 250 000 people. Meningitis strikes with frightening speed. A perfectly healthy child can be playing with friends one minute and literally be dead a few hours later.
In 1996, the only weapon against meningitis was barely useful at all, a short-lasting vaccine that wasn’t effective among young children. Health officials used it to control outbreaks that were already raging, so they called it “medicine after death.” They demanded a better vaccine that could prevent outbreaks.
The WHO and an organization called PATH formed the Meningitis Vaccine Project in 2001. The partners set a target price of 50 cents for the vaccine, which would make it affordable.
But producing a vaccine at that low price required a new approach to drug development. The Meningitis Vaccine Project worked with a Dutch biotech company to obtain key raw materials and arranged a technology transfer from the United States. Then, the Serum Institute of India agreed to manufacture the vaccine at the target price.
I am pleased to announce that we now have very early results from the use of vaccines from Burkina Faso. In the first 16 weeks of this year, there was just a single case of meningitis reported in the country.
It’s too soon to declare victory, but the early data makes me hopeful. For centuries, meningitis terrorized a region of 400 million people. This vaccine can help end the terror.
We need to continue creating and delivering more vaccines, but finally, for the first time, we can see a bright future.
Vaccine coverage
To keep the promise of equitable access to health care, all new vaccines must be priced low enough so that all countries can afford them. The Gates Foundation is working with many vaccine manufacturers to ensure that vaccines are available at a reasonable price. I believe that we can cut the combined price of the pentavalent, pneumococcus, and rotavirus vaccines in half by 2016.
But even when prices are fair, delivering vaccines to every child takes a great commitment.
Many developing countries are already doing a great job. Bangladesh, Nicaragua, Rwanda, and Vietnam routinely reach about 90 percent of their infants. But there are many places where vaccination rates are low. Almost every country can do better, must do better, if this decade is to reach the potential of the Decade of Vaccines.
Leading a health ministry is a hard job. You face a multitude of complicated choices. The stakes are always life and death and you have many priorities.
But you all have access to one key resource: your own leadership. And leadership can be decisive. The best immunization systems work because leaders hold themselves accountable for results. They diagnose problems, innovate to solve them, and spread the best ideas.
Let me give an example. Just a few years ago, the Indian state of Bihar was vaccinating under 30 percent. Then, a new chief minister, Nitish Kumar, was elected, and he made it clear that he expected change.
So even though Bihar is still one of the most challenging places in the world, but it’s no longer one of the least vaccinated. Under Chief Minister Kumar, the vaccination rate has more than doubled, and it plans to go higher.
I visited with Chief Minister Kumar two months ago, and his understanding of what was working and what wasn’t was impressive. He understood the innovations that were being tested.
Examples like this inspire all of us for better leadership. I was also struck by the chief minister’s popularity. People are hungry for visionary leaders who not only promise a better future, but take a basic system and make it work.
Today, I ask for your leadership. In 2005, you set two critically important immunization-related goals that we have not yet reached.
Let us renew our pledge that no country will be below 90 percent coverage. Let us rededicate ourselves to the idea that no district will be below 80 percent coverage. We will meet those goals if, and only if, you lead. With your leadership, you will make this the Decade of Vaccines.
As a global health community, it is imperative that we shine a light on the countries doing the best work. We need to know who the innovators are, so that the most powerful ideas spread far and wide.
Starting in 2012, the Gates Foundation will bestow an award on the individual or organization that has made the most uniquely innovative contribution to the Decade of Vaccines. This could be innovation in the science, delivery, or funding of vaccines. I will announce the winner every January in my annual letter. My goal is to make sure that pioneering global health leaders get the credit they deserve.
Polio
The long fight against polio proves just how powerful vaccine technology can be, but it also demonstrates that it is only as effective as the quality of delivery.
Twenty-three years ago, here in this building, the delegates to this Assembly resolved to wipe polio off the planet. And now we’re 99 percent of the way there, because of two things: a 13 cent vaccine so easy to administer that even I have done it many times; and the most impressive, farthest-reaching delivery effort global health has ever seen.
It is fantastic that more than 100 countries no longer have polio. In the most difficult conditions in the world, we are making stunning progress. Despite the ongoing war, Afghanistan has had only one case this year.
But progress is not the same as success, and eradication is not guaranteed. We have tools: diagnostics, surveillance systems, and vaccines that are constantly being improved, but the virus keeps spreading back into countries where it had been eliminated. There are countries where the virus continues to circulate, despite multiple campaigns every year. Globally, the polio programme is not assured of funding to keep running campaigns and improving vaccination systems.
These discouraging facts raise a question: do we really have the political commitment to eradicate polio?
Are donor countries, especially the G8, ready to close today’s funding gap and see the job through to the very end?
Are the countries where polio still exists ready to take extraordinary action to reach every single child with the vaccine?
We have a choice. We can keep doing what we’ve been doing, immunizing the same children over and over and missing the children who are the most vulnerable. Or we can do more. We can step up our fundraising, we can intensify our campaigns, and we can do what it takes to get to zero cases. If we make that choice, we will prove that people are capable of coming together to solve complex, worldwide problems.
The eradication of polio will be a great victory for this Assembly. You started the courageous fight against this disease. You will finish it. And then you will be able to move on to the next ambitious goal.
One of the polio leaders I respect most is Dr. Muhammad Pate, who directs Nigeria’s national eradication effort. Just a few years ago, Nigeria was the most troublesome spot on the polio map. It had hundreds of cases. Much worse, it lacked the commitment to bringing that number down.
But Dr. Pate, along with the global polio partners, President Goodluck Jonathan, and members of the ministry of health, helped rally government and traditional leaders around the cause. Dr. Pate told me that his agency makes a point of identifying poor-performing states publicly. That’s the kind of accountability that leads to results. Last year, thanks to a nationwide effort, polio was down 95 percent in Nigeria. Nigeria’s leaders still have a lot of work ahead of them, but they have turned the polio programme around.
During my last visit to Nigeria, Dr. Pate asked me a small favor. He hoped I’d be willing to sign his daughter’s school yearbook. I was more than willing, of course, and I want Dr. Pate’s daughter to know this: I admire her father very much, I want to someday introduce my children to him one day soon, and I hope more than anything that when that day comes we shall be celebrating the fact that there is no more polio in Nigeria.
Call to action
The world has a great opportunity right now, and whether or not we seize it will depend in large part on those of us in this room. It will depend on our ability to do the difficult, necessary things to usher in the Decade of Vaccines.
Donor countries, will have to increase investment in vaccines and immunization, even though they are coping with budget crises. The GAVI Pledging meeting in June gives you and your governments the opportunity to show your support. If donors are generous, we will prevent 4 million deaths by 2015. By 2020, we can prevent 10 million deaths.
Pharmaceutical companies, you must make sure vaccines are affordable for poor countries. Specifically, you must make a commitment to tiered pricing.
For all 193 Member States, you must make vaccines a high priority focus of your health systems, to ensure that all your children have access to existing vaccines now, and to new ones that have recently become available.
At the Gates Foundation, we are committed to working with all our partners – civil society, donors, drug companies, and national governments – to help you do the difficult but necessary things.
I am confident because I’ve seen so many examples of leadership.
British Prime Minister David Cameron passed the toughest austerity budget in his country’s memory. Yet, in the face of enormous pressure, he kept his promise to maintain development spending. A few months later, he announced that the United Kingdom would double its commitment to the polio campaign.
Another example is the Serum Institute of India, led by Dr. Cyrus Poonawalla, has broken the mold for the low-cost manufacture of vaccines. They developed the meningitis vaccine, they are the world’s largest producer of the measles vaccines, and they provide the pentavalent vaccine to GAVI at a lower price than any other manufacturer in the world. In the coming years they will manufacture inexpensive diarrhea and pneumonia vaccines.
Nitish Kumar and Muhammad Pate and many others have demonstrated that the best leaders can overcome tough challenges.
Together, and with your leadership, we can make this the decade in which we take full advantage of the technology of vaccines. When we do it, we will build an entirely new future based on the understanding that global health is the cornerstone of global prosperity.
It might be the most difficult thing we’ve ever done, but it will also be the most important.
Luanda — The commemoration of the World Malaria Day this year marks the end of the UN’s roll back malaria decade and offers an opportunity for renewed commitment on the pandemic.
This was said Sunday by the World Health Organisation (WHO) regional director for Africa, Luis Gomes Sambo.
According to him, this affords us an opportunity to renew our common vision and commitment as we look forward and aim at attaining the Millennium Development Goals (MDGs) by 2015.
Malaria, by its complexity involving health as well as environmental and socioeconomic determinants and consequences, relates virtually to all the MDGs, the official also stated, adding that “as it is well known, our part of the world is home to an estimated 795 million people exposed to malaria. Close to 90% of deaths due to malaria worldwide occur in Africa.
Gomes Sambo went on to say that the poor, children, pregnant women, people living with HIV/AIDS, victims of unrest and disasters and non-immune travellers are particularly vulnerable. Therefore, progress in the fight against malaria in Africa is critical to reaching the ambitious targets set in the UN Secretary General’s call for Universal Access to essential interventions, the AU Abuja Declaration and Plan of Action, Resolutions of WHO Governing Bodies and the Roll Back Malaria (RBM) Global Malaria Action Plan (GMAP).
In this regard, he added, it is encouraging to note that malaria control alliances are being strengthened throughout Africa. For example, the African Leaders Malaria Alliance (ALMA) has committed to support elimination of preventable malaria deaths by 2015. The African Union and Regional Economic Communities have also kept malaria high on their health and development agenda.
Countries and partners are making commendable efforts to accelerate and sustain progress in malaria prevention and control in our Region. For example, endemic countries have reflected malaria control in their poverty reduction strategies, the official stated.
Programme reviews are ongoing and strategic plans are being updated to take into account funding and capacity gaps to reach universal access. The success rate for malaria proposals for the Global Fund (GFATM) reached 80% in Round 10. Consequently, effective interventions including protection from the mosquito vector through the use of Insecticide Treated Nets (ITNs) and Indoor Residual Spaying (IRS), prompt treatment of malaria cases using Artemisinin-based combination therapy (ACT), intermittent preventive treatment of malaria in pregnant women (IPTp) and infants (IPTi) are being adapted and scaled up, the WHO regional director also stated.
According to him, cross-border initiatives are catalyzing efforts to accelerate and sustain control and, where possible, to prepare for the transition to pre-elimination. The Affordable Medicines Facility for Malaria (AMFm) has been launched in Ghana, Kenya, Madagascar, Niger, Nigeria, United Republic of Tanzania and Uganda to ensure access to quality ACTs in private sector facilities. Malaria vaccine trials are ongoing in Burkina Faso, Ghana, Gabon, Malawi, Mozambique, Tanzania and Kenya.
As he went on to say, by the end of 2010, a total of 11 countries (Algeria, Botswana, Cape Verde, Eritrea, Madagascar, Namibia, Rwanda, Sao Tome and Principe, South Africa, Swaziland, Zambia and Zanzibar, United Republic of Tanzania) had registered more than 50% reduction in malaria cases and deaths; the proportion of households owning at least one insecticide treated net (ITN) was 42% and 35% of children under five years of age slept under an ITN; 27 countries had reported implementation of Indoor Residual Spraying (IRS) so that 73 million people accounting for about 10% of the population at risk of malaria in the Region were protected by IRS; 33 countries had adopted a policy of parasitological testing of all suspected malaria cases and 35% of malaria cases in the Region were confirmed by a diagnostic test.
In his opinion, in order to consolidate the gains achieved so far, “we need to ensure: rigorous governance to strengthen performance and accountability; mobilization of additional resources; linking disease programme development and health systems strengthening; better coordination of stakeholders and partners under national stewardship; and effective involvement of every exposed individual and community.”
Among the critical challenges that countries need to address are: weak surveillance, monitoring and evaluation capacity; inadequate operational research platforms; lack of implementation of regulatory measures such as the ban on oral Artemisinin-based monotherapies and inadequate monitoring of parasite resistance to antimalarial medications and mosquito resistance to insecticides, he stated.
Gomes Sambo pledged that WHO will continue to work with Member States and partners to mainstream malaria control in health and development policies and plans; mobilize domestic and external funding; foster public private partnerships, support alignment of stakeholders around country priorities and provide guidance and assistance to ensure efficient use of resources for performance and impact. We shall also continue to support initiatives for the removal of taxes and tariffs on malaria commodities, and a ban on the marketing of oral artemisinin monotherapies.
On the other hand, he called upon Governments, parliamentarians, Nongovernmental Organizations, the private sector, civil society groups, faith-based organizations and all exposed communities to take stock of our common achievements and mobilize financial and human resources in a decisive push to further accelerate malaria prevention and control for the socioeconomic progress of countries of the African Region.
The parasite responsible for the intense fevers, chills, and headaches of malaria is very skilled at hiding in the in the body. That means vaccines don’t work all that well to prevent the disease.
So Dutch researchers are trying a new approach — “vaccinating” people by having them get bitten by mosquitoes carrying the malaria parasite, which is similar to how people get infected in the real world. And it seems that this technique may keep people safe from the disease more than two years later.
The Dutch way is different than the conventional vaccine approach of injecting people with bits and pieces of the malaria parasite, or a parasite that’s been weakened in the lab.
Those traditional approaches haven’t been working all that well in clinical trials. The Plasmodium parasite is notoriously tough to manipulate because it spends most of its time hiding inside red blood cells and liver cells, out of sight of the immune system. That’s one reason why it was able to kill 781,000 people in 2009. Most of those were children in developing countries.
In the Dutch experiment, 10 volunteers were bitten multiple times by malarious mosquitoes. The researchers then gave the volunteers an anti-malaria drug, chloroquine. (And yes, the researchers were very careful to pick a malaria type that can be vanquished by chloroquine, not a variety resistant to the drug.)
A couple of years ago, the researchers reported that this process works in the short run to protect against malaria. But that’s not such a big deal. People naturally infected by malaria build up an immunity that holds for several months.
What’s new is that the researchers went back to six of the volunteers 28 months later. Once again the volunteers allowed themselves to be bitten by malarious mosquitoes. Four of the six did not get infected. And the immune systems of the remaining two put up a fight – their infections were delayed (and quickly treated). The results were published online in The Lancet.
Wondering who would volunteer to be bitten by a malarious mosquito? Study author Robert Sauerwein of Radboud University in the Netherlands says most were university students. And the trial was designed pretty carefully.
A lot more work needs to be done to test this approach. This study was very small – only six people. And the researchers note that they may have stacked the deck a little – they used the exact same strain of malaria to infect, and to re-infect. And they worked with adults with mature immune systems, rather than children.
It’s not clear yet why the experimental vaccination protected longer than infection by mosquito in the field. The anti-malarial drug could have helped. Or maybe it was the intense exposure to multiple bites at the same time. Whatever the reason, they say, it’s worth investigating given how well the malaria parasite has been at outsmarting attempts to get rid of it.
It is pertinent to draw the world’s attention to the issue of reparations for Africa once again. This much vilified issue of reparations for Africa seems to have receded to the background particularly since the death of one of its most avid supporters the late Nigerian Business Mogul MKO Abiola.
The question being asked by many informed observers is why the call for reparations for Africa? They opined that Africa is asking for too much and also seeking to be “spoon fed” without basis. They tend to draw analogies between Africa and other continents, particularly Asia with whom Africa shares similar history. They point to the fact that if the continent of Asia could set itself on the path of self discovery and economic and social development, in spite of its dearth of mineral resources, then Africa has no reason to lag behind and continue to call for reparations. They also draw the attention of the pro reparations community to the fact that most African nations have mismanaged loans and development aids granted them by Breton Woods Institutions such as the World Bank, IMF and donor agencies such as the London Club, Paris Club etc. As a matter of fact they assert that Africa is now enmeshed in the debt trap because of the foreign loan mismanagement malaise.
They also pointed out, that Africa has not been able to tap or benefit from robust economic packages like the ambitious AGOA [African Growth and Opportunities Act] signed into law by the former American President, Bill Clinton, which sought to provide leverage for African goods in the American market. The weakening of institutions of state and absence of democracy in the true sense of the word in most parts of Africa has also been fingered as one of the reasons why the quest for reparations is untenable.
The sound and forceful logic of the anti- reparations community in rejecting calls for reparations for Africa may be compelling but there is a need to expand the frontiers of the question from “why reparations?” to “what is reparation?”. Reparations may be conceptualized as compensation especially monetary, paid to countries or people who have been subjected to severe deprivations and degradations which consequently leads to a pronounced disadvantage.
The history of the African continent through several epochs and eras in world history which is well documented is replete with severe deprivations and human degradations, accompanied by so much bloodshed. This includes the slave trade, colonization, imperialism, resource exploitation, proxy wars religious inquests and so on. It may be averred that a correlation, maybe not so significant, can be drawn between these events and the present state of the African continent. Hence the call for reparations may NOT out rightly be out of order.
It is to this end, that a call for reparations is made, and such compensations should be channeled to critical areas such as the endemic scourge of malaria on the African continent, pandemic scourge of HIV/AIDS, famine in Africa, humanitarian displacement [Refuge problems] that are all still prevalent problems in the continent
Scientists call for more research, conservation of trees to harvest potential for next generation of malaria drugs
A scientist holding Warburgia ugandensis plant (world Agroforestry Center)
NAIROBI (21 April 2011)— Research released in anticipation of World Malaria Day finds that plants in East Africa with promising antimalarial qualities—ones that have treated malaria symptoms in the region’s communities for hundreds of years—are at risk of extinction. Scientists fear that these natural remedial qualities, and thus their potential to become a widespread treatment for malaria, could be lost forever.
A new book by researchers at the World Agroforestry Centre (ICRAF) and the Kenya Medical Research Institute (KEMRI), Common Antimalarial Trees and Shrubs of East Africa, provides a detailed assessment of 22 of the region’s malaria-fighting trees and shrubs. While over a thousand plant species have been identified by traditional healers as effective in the prevention or treatment of malaria symptoms, the species in the book were assigned by both traditional medicinal practitioners and scientists as those that have potential for further study.
According to researchers, many species of trees in East Africa are at high risk of extinction due to deforestation and over-exploitation for medicinal uses. Scientists in the field have been able to identify at-risk tree species, including those that have antimalarial qualities, by monitoring deforestation in the region and by talking to herbalists and local communities. According to researchers, not all species of antimalarial trees are at risk, particularly those that grow wild in lowland and coastal areas.
ICRAF is doing its part preserving these trees and shrubs by holding samples of most of the species with antimalarial qualities in its genebank and growing these trees in plant nurseries at its headquarters in Nairobi. The ICRAF genebank holds close to 200 species, of which at least 30 are known to have antimalarial properties.
The field data was gathered by ICRAF scientists conducting research across Kenya, Uganda, and Tanzania, where they met with approximately 180 herbalists and 100 malaria patients in 30 separate communities. KEMRI supported the process by supplying the information about each plant’s chemical compound make-up—research that is the result of a sophisticated laboratory process developed by KEMRI for testing natural products.
“We’ve only scratched the surface on the potential value of these plants. Although widely used by farmers and people in rural communities, most of this information has never been collected in a comprehensive way by researchers,” said Dr. Geoffrey Rukunga, Director of KEMRI’s Centre for Traditional Medicine and Drug Research and one of the book’s co-authors. “Going forward, I’d like to see more investment and more research on the power of these plants to fight the scourge of malaria and other diseases.”
One of the drugs most widely used historically to treat malaria, quinine, was derived from the bark of the Cinchona tree in South America. Today, the world’s newest, most-effective therapeutic treatment for malaria also comes from a plant, the Artemisia annua shrub. However, access to malaria therapies based on artemisinin compounds remains low—around 15 percent in most parts of Africa and well below the World Health Organizations’ 80 percent target.
Additionally, the malaria parasite’s ability to resist artemisinin is already beginning to emerge in Southeast Asia. This comes years after the World Health Organization labeled the spreading resistance of malaria to cheap and widely available drugs such as chloroquine and sulfadoxine-pyrimethamine as a major public health problem. The increasing failure of once-effective malaria drugs has added urgency to the search for promising new targets.
Malaria still kills some 800,000 people per year, the majority of whom are children under five years of age in sub-Saharan Africa. A lack of access to doctors and drugs leaves many communities in Africa with few alternatives other than looking for natural remedies to address symptoms of malaria, including high fever, severe headaches, bone aches, nausea and vomiting.
“We’re not saying that using these medicinal plants is a replacement for common prevention treatments like bed nets or effective medicines like ACT,” said Dr Najma Dharani, a Consultant Research Scientist at the ICRAF in Nairobi, Kenya, who led the field research portion of the study. “But we believe that it’s worth learning from communities that have been treating malaria symptoms with plants for hundreds of years. We need to do more research because one of these plants could prove to be the next Artemisia, and we need to do our best to preserve the plants that are going extinct.”
Indeed, without clear research or proper guidance for their sustainable use, many of the plants with medicinal properties are being over-exploited and are in danger of extinction. One such plant, which is critically endangered in Kenya and threatened in other regions, is Zanthoxylum chalybeum, commonly known as “Knobwood.” It grows in dry woodlands or grasslands of eastern and southern Africa and has been found to have antimalarial properties that need to be further explored. An extraction process from leaves, bark or root is used to effectively treat a malarial fever in many communities. Other uses for the plant include infusing tea with the leaves, making toothbrushes, and using the seeds as beads in traditional garments.
The African wild olive (Olea europaea Africana), also threatened in East Africa due to over-exploited for timber, contains organic extracts with significant levels of antimalarial activity, and is used to treat malarial and other fevers. The plant also acts as a natural laxative to expel parasites or tapeworms.
“Throughout my eight years of research in Africa, I have seen that we have an entire pharmacy in our farms and in our forests. We have plants that should be used by scientific companies to develop more options for malaria drugs,” said Dr. Dharan. “And we cannot become complacent and rely on one herb, because we’ve learned that developing resistance is likely.”
Beyond the complicated process to extract and test antimalarial compounds from these trees, scientists have struggled to track or replicate the treatment process as it occurs in communities. Besides the plant itself, there may be other factors contributing to a malaria patient’s recovery. For example, a healer may combine one plant with another that changes its chemical compound and boosts its effectiveness. Unless more is done to understand these processes in the field, scientists in laboratories and researchers at major drug companies will lose that knowledge.
“While we’ve made scientific progress identifying these compounds over the last few years, the fact is that we may lose these important trees before we’ve had a chance to understand their ability to defend us against malaria, a disease that devastates Africa—killing hundreds of thousands of our children and costing us billions of dollars in productivity year after year,” said Dr. Rukunga. “We need to approach this as an opportunity on multiple fronts: to preserve the biodiversity that may hold the next cure, to strengthen the research done on the ground in communities, and to continue our diligent work testing our natural resources in the lab.”
###
The World Agroforestry Centre (ICRAF) is an autonomous, non-profit research organisation whose vision is a rural transformation in the developing world resulting in a massive increase in the use of trees in rural landscape by smallholder households for improved food security, nutrition, income, health, shelter, energy and environmental sustainability. The Centre generates science-based knowledge about the diverse roles that trees play in agricultural landscapes, and uses its research to advance policies and practices that benefit the poor and the environment. We are one of the 15 centres of the Consultative Group on International Agricultural Research (the CGIAR). http://www.worldagroforestrycentre.org/
The Kenya Medical Research Institute(KEMRI) was established in 1979 as the national body responsible for carrying out health science research in Kenya. Since then, KEMRI has served as a centre of excellence for health research in Africa. It works closely with the Kenyan Ministry of Health and various national councils and committees on issues of policy and priorities. The institute accomplishes its mandate through research centres that are intended to focus on certain specific areas of national and/or strategic importance. The centre that conducts research on herbal medicines is the Centre for Traditional Medicine and Drug Research (CTMDR). This centre studies the chemical composition, efficacy and safety of traditional medicines, and the socio-cultural and anthropological basis of the use of herbal remedies. http://www.kemri.org/
A team of graduate students has created a new smartphone application they say will allow healthcare workers in remote locations to diagnose malaria cases on the spot.
But first, the students hope their application wins this weekend’s Imagine Cup 2011 national finals in Seattle.
The 9th-annual Imagine Cup, sponsored by Microsoft, asks student entrants to “imagine a world where technology helps solve the toughest problems.”
Tristan Gibeau, 25, a graduate computer engineering student at the University of Central Florida in Orlando, said his team’s application fits the bill.
“It’s going to make a difference in trying to contain the outbreak of malaria,” said Gibeau, the project’s software designer.
“In the big picture, it’ll hopefully help in the fight against most diseases out there and make everybody’s life a little easier.”
His team’s prototype is a Windows 7-equipped Samsung Focus smart phone modified with a microscopic camera lens.
Gibeau said the software application can take a picture of a blood sample, process the data to detect malaria parasites, quantify how much malaria is in the sample and point the parasites out to the phone user.
“It actually draws a red box around the clusters of malaria, and it actually notifies you how many it found,” Gibeau said.
Although microscopic lenses are already available for smart phones, Gibeau said the software takes the concept’s usefulness to another level.
It would enable a doctor or nurse working, for example, in an African village lacking Internet access to make a diagnosis without having to upload data for processing elsewhere.
However, once the data stored in the phone is uploaded, it can be used to spot disease trends, Gibeau said.
He said he is working on smart phone applications to detect sickle cell and other diseases and also plans to make the software easily adaptable to lab-based microscopes.
The smart phone application was the idea of team member Wilson To, a 25-year-old graduate student in comparative pathology at the University of California at Davis.
It builds upon a mobile microscope concept that To and a different team created to win last year’s Imagine Cup national finals.
Gibeau said the team is working toward patenting and marketing the new application.
“From different conversations we’ve had with investors, we feel that this definitely is a money-maker,” he said.
Global health experts said on Thursday that the world’s most powerful drugs are losing the battle against drug-resistant strains of malaria, HIV, gonorrhea and tuberculosis
According to Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention, antimicrobial resistance is robbing us of the certainty that antibiotics will always be there to fight infections and new drug-resistant pathogens are emerging. “It’s not enough to hope that we’ll have effective drugs to combat these infections. We must all act now to safeguard this important resource,” Frieden said
What you need to know about Anti-Microbial Resistance
What is Anti-Microbial Resistance:
Antimicrobial resistance occurs when germs change in a way that reduces or eliminates the effectiveness of drugs to treat them. This happens when antibiotics, antivirals, antifungals and other medications are used too liberally. About half of antimicrobial drugs — antibiotics in particular — are used unnecessarily or inappropriately prescribed in U.S. hospitals and in doctors’ offices, the CDC says. The best approach to preserving those drugs is to use them only when needed.
How Anti-Microbial Resistance affects developing world, especially Africa
HIV: Studies show that up to 20 percent of newly diagnosed HIV patients have transmitted a drug-resistant infection. Approximately 22 million people live with HIV in Sub-Saharan Africa. In the US and other developed countries, Doctors can test or resistance before prescribing drugs, but such luxury may be too hard to come by in under-privileged communities
Malaria: Plasmodium falciparum, the most dangerous of the malaria parasites, has developed resistance in nearly all areas of the world where it is transmitted. Annually, there are about 225 million malaria infections and nearly 800,000 deaths. Women and children are the most affected, particularly in Sub-Saharan Africa.